Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123145153 | 12314515 | 3 | F | 20160721 | 20160428 | 20160727 | EXP | US-GLAXOSMITHKLINE-US2016GSK059251 | GLAXOSMITHKLINE | CHA A, ELSAMADISI P, SU CP, PHIPPS E, BIRNBAUM JM. PREVENTION OF PERINATAL TRANSMISSION OF ZIDOVUDINE AND NEVIRAPINE-RESISTANT HIV. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY. 2016;73 (7):451-455 | 17.00 | YR | F | Y | 0.00000 | 20160727 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123145153 | 12314515 | 1 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Intravenous (not otherwise specified) | 2 MG/KG, UNK | U | 0 | 2 | MG/KG | |||||||
| 123145153 | 12314515 | 2 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Intravenous (not otherwise specified) | 1 MG/KG, CONTINUOUS INFUSION | U | 0 | 1 | MG/KG | |||||||
| 123145153 | 12314515 | 3 | SS | Nelfinavir mesylate | NELFINAVIR MESYLATE | 1 | 625 MG TABLET DISSOLVED IN 20 ML OF STERILE WATER YIELDING 31.25 MG/ML | U | 0 | 31.25 | DF | ||||||||
| 123145153 | 12314515 | 4 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | U | 20564 | |||||||||||
| 123145153 | 12314515 | 5 | SS | TENOFOVIR DISOPROXIL FUMARATE. | TENOFOVIR DISOPROXIL FUMARATE | 1 | 300 MG, QD | U | 0 | 300 | MG | QD | |||||||
| 123145153 | 12314515 | 6 | SS | RITONAVIR. | RITONAVIR | 1 | 100 MG, QD | U | 0 | 100 | MG | QD | |||||||
| 123145153 | 12314515 | 7 | SS | EMTRICITABINE | EMTRICITABINE | 1 | 200 MG, QD | U | 0 | 200 | MG | QD | |||||||
| 123145153 | 12314515 | 8 | SS | ATAZANAVIR | ATAZANAVIR | 1 | 300 MG, QD | U | 0 | 300 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123145153 | 12314515 | 1 | HIV infection |
| 123145153 | 12314515 | 3 | HIV infection |
| 123145153 | 12314515 | 4 | HIV infection |
| 123145153 | 12314515 | 5 | HIV infection |
| 123145153 | 12314515 | 6 | HIV infection |
| 123145153 | 12314515 | 7 | HIV infection |
| 123145153 | 12314515 | 8 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123145153 | 12314515 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123145153 | 12314515 | Exposure during pregnancy | |
| 123145153 | 12314515 | Live birth | |
| 123145153 | 12314515 | Pathogen resistance | |
| 123145153 | 12314515 | Prolonged rupture of membranes | |
| 123145153 | 12314515 | Treatment noncompliance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |